Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
US7807186B2 · kind B2 · utility
1Cited by
3References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 16, 2008 |
| Grant date | Oct 5, 2010 |
| Priority date | — |
| Expiry date | Feb 11, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.